/RNAZ

RNAZ Stock - TransCode Therapeutics, Inc.

Q: What is the analyst price target for RNAZ?

Analyst price target information is not currently available for RNAZ.

Q: What is RNAZ's market cap?

Market capitalization information is not currently available for RNAZ.

Healthcare|Biotechnology|NASDAQ

$7.92+0.89%

+$0.07 (+0.89%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $8.71

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RNAZ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.53

52W High$468.44

52W Low$6.15

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-534,857	$-516,746	$-98,606	$-42,470	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-15,660,697	$-19,418,516	$-18,665,814	$-6,151,135	$-726,604
Net Income	$-16,754,971	$-18,546,095	$-17,564,968	$-6,843,399	$-2,343,893
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-47.14	$-3453.65	$-73187.37	$-648.00	$-293.76

Company Overview

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Visit Website

Earnings History & Surprises

RNAZ

Beat Rate

53%

Last 15 quarters

Avg Surprise

-211476.2%

EPS vs Estimate

Beats / Misses

8/7

Last 12 quarters

Latest EPS

$-5.49

Q4 2025

EPS Surprise History

Q1 24

-825.8%

$-99.99vs$-10.80

Q2 24

+7.1%

$-21.45vs$-23.10

Q3 24

-27.6%

$-24.42vs$-19.14

Q4 24

+67.3%

$-5.28vs$-16.17

Q1 25

+84.3%

$-16.61vs$-105.93

Q2 25

-423.7%

$-16.81vs$-3.21

Q3 25

+43.1%

$-4.94vs$-8.68

Q4 25

+40.6%

$-5.49vs$-9.24

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 14, 2025	$-9.24	$-5.49	+40.6%	✓ BEAT
Q3 2025	Aug 14, 2025	$-8.68	$-4.94	+43.1%	✓ BEAT
Q2 2025	May 14, 2025	$-3.21	$-16.81	-423.7%	✗ MISS
Q1 2025	Mar 28, 2025	$-105.93	$-16.61	+84.3%	✓ BEAT
Q4 2024	Nov 14, 2024	$-16.17	$-5.28	+67.3%	✓ BEAT
Q3 2024	Aug 14, 2024	$-19.14	$-24.42	-27.6%	✗ MISS
Q2 2024	May 15, 2024	$-23.10	$-21.45	+7.1%	✓ BEAT
Q1 2024	Mar 29, 2024	$-10.80	$-99.99	-825.8%	✗ MISS
Q4 2023	Nov 14, 2023	$-1980.20	$-2217.82	-12.0%	✗ MISS
Q3 2023	Aug 14, 2023	$-4475.25	$-4343.23	+3.0%	✓ BEAT
Q1 2023	Mar 31, 2023	$-10033.00	$-10297.03	-2.6%	✗ MISS
Q1 2023	Mar 30, 2023	$-0.38	$-0.23	+39.5%	✓ BEAT
Q4 2022	Nov 14, 2022	$-10561.06	$-8712.87	+17.5%	✓ BEAT
Q3 2022	Aug 15, 2022	$-0.30	$-9504.95	-3168216.7%	✗ MISS
Q2 2022	May 16, 2022	—	$-7128.71	—	—
Q1 2022	Mar 31, 2022	$-200.00	$-6072.61	-2936.3%	✗ MISS
Q4 2021	Nov 15, 2021	—	$-5280.53	—	—
Q3 2021	Aug 23, 2021	—	$589.73	—	—
Q3 2021	Jul 9, 2021	—	$-278.07	—	—
Q4 2020	Dec 31, 2020	—	$-100.46	—	—

Frequently Asked Questions about RNAZ

What is RNAZ's current stock price?

TransCode Therapeutics, Inc. (RNAZ) is currently trading at $7.92 per share. The stock has moved +0.89% today.

What is the analyst price target for RNAZ?

No analyst price targets are currently available for this stock.

What sector is TransCode Therapeutics, Inc. in?

TransCode Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RNAZ's market cap?

TransCode Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.

Does RNAZ pay dividends?

No, TransCode Therapeutics, Inc. does not currently pay a dividend to shareholders.